Adapting cutting edge technologies

The TriviumVet pipeline comprises innovative treatments for diseases where there are no specific veterinary approved drugs.

Our focus is on adapting cutting edge technology developed for human medicine to improve the accessibility for our pets.

Our therapeutic candidates are formulated for species specific suitability, tested for safety and efficacy and are then submitted to the FDA (Center for Veterinary Medicine) and the EMA European Medicines Agency (CVMP) for approval.

Our Pipeline

TRIV-201O

Canine Gastric Ulcer Disease

TRIV-203F

Feline Cardiomyopathy

TRIV-202F

Canine Cardiac Disease

TRIVI-206DiaH

Equine Diagnostic

TRIVI-207DiaC

Canine Diagnostic

TRIV-205B

Canine Neuropathic Pain

TRIV-204T

Canine Oncology